12 2020 . » () COVID-19. 1 ( : , » Ȕ, )
() — , , . , , , , , .
, — (), , , , , . , , MERS-CoV SARS-CoV-2 ( COVID-19), . , , .
1.
. 30 . . -, -. , 3-5 .
SARS-CoV-2 2019. 2020., . ( 84% ). 2020. COVID-19, . 2020. COVID-19 , , , . 11 2020. COVID-19.
, COVID-19 , . -, — .
COVID-19 2020. . , COVID-19. , COVID-19.
2. COVID-19
COVID-19 , , (, , -, , MERS-CoV, ), , .
, , 3 , COVID-19 1 14 , 5 . , COVID-19 , , . COVID-19, , , . , . , COVID-19.
, COVID-19 (), .
, ( 37,5 C : — , , , (SpO2) 95%, , ) , COVID-19.
3. COVID-19 10- (-10)
-10 :
J00-06
J00 ,
J02
J02.8 ,
J02.9
J03
J03.8 ,
J03.9
J04
J04.0
J04.1
J04.2
J05 ()
J05.0 ()
J06
J06.0
J06.8
J06.9
J20-J22
J20
J20.4 ,
J20.5 ,
J20.6 ,
J20.8 ,
J20.9
J21
J21.0 ,
J21.8 ,
J21.9
J22
B34.0
B34.2
B34.9
B97.0
B97.4 —
U07.1 COVID-19, ( )
U07.2 COVID-19, (COVID-19 , )
Z03.8
Z20.8
4. COVID-19
— . , , , . , ( 48 ), .
. , , , .
, , . , c .
(: :), / (:), 2- (:, :). , , .
, , . , . .
, .
( ) 2b , : :, : , :, : .
, , .
1.
COVID-19 , , : :, :, : +, : ( 2).
, in vitro, COVID-19, :, :, : .
COVID-19 ( ), ( ), ( COVID-19), , , , SARS-CoV-2.
, . . , 65 ( , — , , .) COVID-19, .
:
1. 38,5 ;
2. 22 .;
3. (SpO2) 95%;
4. ;
5. .
. .
COVID-19 , SARS-CoV-2. : :, . . COVID-19.
1. . 5 ( — 3000 ME, — 15000-18000 ME) + 600 (3 200 ), 400 (2 200 ), 200 7 .
2. . 5-6 ( — 3000 ME, — 15000-18000 ME) + 500 (2 250 ), 250 7 .
3. : 200 4 + 600 (3 200 ), 400 (2 200 ), 200 7 .
4. : 200 4 + 500 (2 250 ), 250 7 .
5. . 5-6 ( — 3000 ME, — 15000-18000 ME) + , 200 4 — 5 .
COVID-19, ( ).
, «off-label» ( ), , , 21 2011. N323- » «, 12 2010. N61- » «, 14155-2014 » «, 1 2016. N200 » » ( 23 2016., N43357), () , 64- , , , 2013.
, , . COVID-19 COVID-19, «off-label» COVID-19 , , «off-label».
1. «, (COVID-19), ., 2020.
2. , , SARS-CoV-2 ., 2020.
3. » «, 2017.
4. — 2015-2016 2016-2017. / .., .., .., .., .., ../. . N4. 2017. .4-13
5. , , / .., ../ . 2018. 15. .82 — 88
6. . » : ( ) , . «, ., 2019.
7. Colson, P., Rolain, J.M., Lagier, J.C., Brouqui, P., Raoult, D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 International Journal of Antimicrobial Agents 2020.
8. Jeong S.Y. et al. MERS-CoV Infection in a Pregnant Woman in Korea. J Korean Med Sci. 2017 Oct;32(10):1717-1720. doi: 10.3346/jkms.2017.32.10.1717.
9. The Centers for Disease Control and Prevention (CDC). Interim guidance for healthcare professionals on human infections with 2019 novel coroirus (2019-nCoV). URL: https://www.cdc.gov/coroirus/2019-nCoV/hcp/index.html
10. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coroirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 Mar 12:105938. doi: 10.1016/j.ijantimicag.2020.105938.
11. Amici C9, Di Caro A, Ciucci A, Chiappa L, Castilletti C, Martella V, Decaro N, Buooglia C, Capobianchi MR, Santoro MG. Indomethacin has a potent antiviral activity against SARS coroirus. Antivir Ther. 2006;11(8):1021-30.
1
( )
—
—
—
——————————
* () .
——————————
,
2
, COVID-19
— , .. , «- — «;
— ., » — ..» ;
— . .. ;
— , » » ;
— » — ..» , — , ,
— ..;
— . .. ;
— . .. ;
— . .. ;
— , . .. .
. .
- Haeser, «Handbuch der Gesch. d. Medicin».
- Харенко Е. А., Ларионова Н. И., Демина Н. Б. Мукоадгезивные лекарственные формы. Химико-фармацевтический журнал. 2009; 43(4): 21–29. DOI: 10.30906/0023-1134-2009-43-4-21-29.
- Bangun H., Aulia F., Arianto A., Nainggolan M. Preparation of mucoadhesive gastroretentive drug delivery system of alginate beads containing turmeric extract and anti-gastric ulcer activity. Asian Journal of Pharmaceutical and Clinical Research. 2019; 12(1):316–320. DOI: 10.22159/ajpcr.2019.v12i1.29715.
- https://www.garant.ru/products/ipo/prime/doc/73787773/.
- З.С. Смирнова, Л.М. Борисова, М.П. Киселева и др. Противоопухолевая активность соединения ЛХС-1208 (N-гликозилированные производные индоло[2,3-а]карбазола) // Российский биотерапевтический журнал 2010. № 1. С. 80.
